# Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir

> **NCT02511431** · PHASE2 · COMPLETED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 22 (actual)

## Conditions studied

- Hepatitis D

## Interventions

- **DRUG:** Lonafarnib
- **DRUG:** Ritonavir
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02511431
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-29
- **Primary completion:** 2017-02-23
- **Final completion:** 2017-02-23
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2018-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02511431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02511431, "Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02511431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*